Transparency Market Research

Use of Peptide
Therapeutics in Treatment
of Diverse Medical
Conditions Stimulates
Market Growth

Buy Now
Request Sample

Published Date: Aug 2013

and Forecast, 2013 - 2019

Single User License: US $ 4595
Multi User License: US $ 7595

104 Pages Report

Corporate User License: US $ 10595

REPORT DESCRIPTION
Use of Peptide Therapeutics in Treatment of Diverse Medical Conditions
Stimulates Market Growth: Transparency Market Research
According to a new market study released by Transparency Market Research (TMR), the global
peptide therapeutics market will be valued at US$23.7 bn by 2020, increasing from its 2013
valuation of US$18.9 bn. If the projected figure hold true, the market will rise at a moderate
2.8% CAGR from 2014 to 2020. The report is titled Peptide Therapeutics Market - Global
Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 and is
available for sale on the company website.
Browse the full Peptide Therapeutics Market (by Applications, by Route of
Administration, and by Marketing Status) - Global Industry Analysis, Size, Share,
Growth, Trends and Forecast 2014 - 2020 report
at http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

Therapeutic peptides have received acceptance in the treatment of several diseases such as
metabolic disorders, cancer, nervous system disorders, gastrointestinal disorders,
acromegaly, hematological disorders, cardiovascular disorders, infections, and respiratory

disorders, among others. Due to the efficacy of peptides for the treatment of a large number
of medical conditions, further research and development has resulted in a rich pipeline of
novel peptides that deliver better therapeutic effects.
Though animal sources such as venom constitute the major source for peptide research,
microbial sources are also being examined for their efficacy for treatment of various medical
conditions. The growing variety of sources as well as applications of peptide therapeutics is
boosting growth prospects of the global peptide therapeutics market. However, despite
extensive research, oral administering of therapeutic peptides still remains a challenge for
researchers, which is indirectly hampering the peptide therapeutics market. Unfavorable
physiological conditions such as the presence of proteolytic enzymes and acidic pH pose a
challenge for oral administering of peptide therapeutics. Moreover, low intestinal penetrability
of peptides also adds to the low bioavailability of these substances.
Lately, a strong trend has been observed in the peptide therapeutics market: whilst new
peptide therapeutic drugs receive regulatory permission, several older peptide therapeutic
drugs will go off-patent during the forecast period. In addition, difficulties associated with
imitating the precise effects of biologics are a major reason for generic drug manufacturers
to face drug approval issues. Thus, generic peptide therapeutic drugs are priced only 70-80%
as much as branded peptide therapeutics. Due to this price gap, high demand for generic
versions is expected to help the peptide therapeutics market overcome its restraints.
Get Sample Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418
Presently, the generic peptide therapeutic leuprolide is retailed under the brand names
Eligard, Lupron, and Enantone, of which Lupron and Enantone constitute sales over US$800
mn across the world.On the competitive front, currently, Teva Pharmaceutical Industries Ltd.,
Novo Nordisk, and Takeda Pharmaceutical Co. Ltd. collectively account for more than 50% of
the global peptide therapeutics market. However, the patent expiration of Copaxone in 2014
and Velcade in 2017 will lead to launch of their generic alternatives. Some other prominent
players in the global peptide therapeutics market are AstraZeneca plc, Eli Lilly & Co., Merck
& Co., Novartis International, and AbbVie Inc.
The global peptide therapeutics market has been segmented as below:
Global Peptide Therapeutics Market, by Application
o Cancer
Zoladex (goserelin)
Velcade (bortezomib)
Lupron/ Enantone/ Eligard (leuprorelin)
Others
o Cardiovascular
Angiomax (bivalirudin)
Integrilin (eptifibatide)

Central Nervous System

Copaxone (glatiramer)
o Metabolic Disorders
Victoza (liraglutide)
Byetta (exenatide)
Others
o Infection
Incivek (telaprevir)
Victrelis (boceprevir)
o Hematological Disorders
Firazyr (icatibant)
Kalbitor (ecallantide)
o Gastrointestinal Disorders
Gattex (teduglutide)
Linzess (linaclotide)
o Respiratory Disorders
o Acromegaly
o Other Applications
Global Peptide Therapeutics Market, by Route of Administration
o Parenteral
o Oral
Global Peptide Therapeutics Market, by Marketing Status
o Branded
o Generic
Global Peptide Therapeutics Market, by Geography
o North America
o Europe
o Asia Pacific
o Rest of the World
o

Get Sample Report:

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418
Table of content
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations
1.5 Assumptions and Stipulations
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview

3.1 Introduction
3.2 Emerging Trends in Peptide Therapeutics Market
3.2.1 Trends in Peptide Manufacturing Technology
3.2.2 Trends in Peptide API Supply
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of
new peptides
3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
3.3.1.3 Technological advancements have reduced total production cost of peptides
3.3.2 Restraints
3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
3.3.2.2 Lack of regulatory standards
3.3.3 Opportunities
3.3.3.1 Generic peptides market to flourish with patent cliff expected during the
forecast period
3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore
further growth
3.4 Regulatory Scenario
3.5 Porters Five Forces Analysis: Global Peptide Therapeutics Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyer
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Event Impact Analysis
3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography,
2013
3.8 Market Share Analysis
Chapter 4 Global Peptide Therapeutics Market, by Applications
4.1 Introduction
4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 2020 (USD
Million)
4.2 Cancer
4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2012 2020 (USD Million)
4.2.2 Zoladex (goserelin)
4.2.3 Velcade (bortezomib)
4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
4.2.5 Others
4.3 Cardiovascular
4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012
2020 (USD Million)
4.3.2 Angiomax (bivalirudin)
4.3.3 Integrilin (eptifibatide)
4.4 Central Nervous System
4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 2020
(USD Million)

4.4.2 Copaxone (glatiramer)

4.5 Metabolic Disorders
4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 2020
(USD Million)
4.5.2 Victoza (liraglutide)
4.5.3 Byetta (exenatide)
4.5.4 Others
4.6 Infection
4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2012 2020 (USD Million)
4.6.2 Incivek (telaprevir)
4.6.3 Victrelis (boceprevir)
4.7 Hematological Disorders
4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 2020
(USD Million)
4.7.2 Firazyr (icatibant)
4.7.3 Kalbitor (ecallantide)
4.8 Gastrointestinal Disorders
4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012
2020 (USD Million)
4.8.2 Gattex (teduglutide)
4.8.3 Linzess (linaclotide)
4.9 Respiratory Disorders
4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020
(USD Million)
4.10 Acromegaly
4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 2020 (USD
Million)
4.11 Other Applications
4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2012 - 2020
(USD Million)
Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 2020 (USD Million)
5.2 Parenteral Route of Administration
5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration,
2012 - 2020 (USD Million)
5.3 Oral Route of Administration
5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration,
2012 - 2020 (USD Million)
Chapter 6 Global Peptide Therapeutics Market, by Marketing Status
6.1 Introduction
6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020
(USD Million)
6.2 Branded Peptide Therapeutics
6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
6.3 Generic Peptide Therapeutics
6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview

7.1 Introduction
7.1.1 Global Peptide Therapeutics Pipeline Overview
Chapter 8 Global Peptide Therapeutics Market, by Geography
8.1 Introduction
8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD
Million)
8.2 North America
8.2.1 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
8.3 Europe
8.3.1 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
8.5 Rest of the World
8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Get Sample Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418
Chapter 9 Recommendations
9.1 Rigorous research and development (R&D) would yield new products
9.2 Facility expansion in emerging economies
9.3 Rapid inorganic growth through acquisitions
Chapter 10 Company Profiles
10.1 Amgen, Inc.
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.5 Recent Developments
10.2 AstraZeneca plc
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.5 Recent Developments
10.3 Bachem Holding AG
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.3.5 Recent Developments
10.4 CordenPharma International GmbH
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.5 Recent Developments
10.5 Eli Lilly and Company

10.5.1 Company Overview

10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.5 Recent Developments
10.6 Ipsen S.A.
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.6.5 Recent Developments
10.7 Lonza Group Ltd.
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.7.5 Recent Developments
10.8 Merck & Co., Inc.
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.5 Recent Developments
10.9 Novartis AG
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.9.5 Recent Developments
10.10 Novo Nordisk A/S
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.5 Recent Developments
10.11 PolyPeptide Group
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.11.5 Recent Developments
10.12 Roche Holdings AG
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.5 Recent Developments
10.13 Sanofi
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio

10.13.4 Business Strategies

10.13.5 Recent Developments
10.14 Takeda Pharmaceutical Company Limited
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.14.5 Recent Developments
10.15 Teva Pharmaceutical Industries Ltd.
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.15.5 Recent Developments
Get Sample Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418
About Us:
Transparency Market Research is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants,
who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
Transparency Market Research
Mr. Sudip.S
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/